Mayne Pharma Group Ltd (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Ltd (ASX: MYX)
Latest News
Share Market News
Returning capital: These ASX companies have been buying back their shares in 2023
Share Fallers
‘Attractive valuation’: 2 ASX shares QVE analysts just bought
Share Fallers
Why Appen, Bank of Queensland, Kogan, and Mayne Pharma shares are dropping
Share Gainers
Why Arafura, Core Lithium, Mayne Pharma, and Newcrest shares are storming higher
Share Market News
Multiple directors are buying this beaten-up ASX 300 healthcare stock
Share Market News
4 ASX 300 directors buying up their company shares in the past week
Share Gainers
Why Allkem, Argosy Minerals, Mayne Pharma, and NextDC shares are racing higher
Earnings Results
Guess which ASX 300 share has rocketed 27% in 2 days since reporting
Share Gainers
Why De Grey, Kogan, Mayne Pharma, and Mesoblast shares are charging higher
Share Fallers
Why Gold Road, MA Financial, Mayne Pharma, and Westgold shares are dropping today
Share Market News
Why Arafura, Mayne Pharma, Pilbara Minerals, and Tyro shares are dropping today
Share Fallers
Why Coronado, IDP, Mayne Pharma, and Rio Tinto shares are dropping today
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
18 Jan 2023 | $0.0272 | 100.00% | Special Cash | 27 Jan 2023 |
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Mayne Pharma Group Ltd
Mayne Pharma is a small generics and specialty pharmaceutical manufacturer that earns over 90% of revenue in the U.S. market. Product portfolios focus on dermatology and women's health. The company performs very limited research and development, typically acquiring off-patent or tail-end brands. In fiscal 2019 generics contributed 61% of revenue and specialty brands 17%, with the balance coming from non-U.S. sales and contract manufacturing. Dynamics within the U.S. genericsmarket leading to increased competition and significant drug price declines have resulted in Mayne significantly impairing acquired intangible assets. The company is shifting its focus to growth of the higher-margin specialty brands segment.
MYX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 Aug 2023 | $4.59 | $0.19 | 4.32% | 182,517 | $4.40 | $4.65 | $4.40 |
08 Aug 2023 | $4.40 | $-0.08 | -1.79% | 97,612 | $4.50 | $4.54 | $4.37 |
07 Aug 2023 | $4.48 | $-0.19 | -4.07% | 134,521 | $4.59 | $4.63 | $4.47 |
04 Aug 2023 | $4.67 | $0.02 | 0.43% | 34,604 | $4.52 | $4.67 | $4.52 |
03 Aug 2023 | $4.65 | $0.05 | 1.09% | 123,745 | $4.55 | $4.66 | $4.50 |
02 Aug 2023 | $4.60 | $-0.22 | -4.56% | 117,171 | $4.80 | $4.80 | $4.56 |
01 Aug 2023 | $4.82 | $-0.06 | -1.23% | 86,176 | $4.88 | $4.93 | $4.80 |
31 Jul 2023 | $4.88 | $0.14 | 2.95% | 219,540 | $4.78 | $4.90 | $4.72 |
28 Jul 2023 | $4.74 | $0.09 | 1.94% | 193,244 | $4.64 | $4.77 | $4.59 |
27 Jul 2023 | $4.65 | $0.04 | 0.87% | 168,667 | $4.61 | $4.66 | $4.53 |
26 Jul 2023 | $4.61 | $-0.07 | -1.50% | 105,231 | $4.72 | $4.72 | $4.61 |
25 Jul 2023 | $4.68 | $-0.05 | -1.06% | 131,229 | $4.73 | $4.73 | $4.60 |
24 Jul 2023 | $4.73 | $0.06 | 1.28% | 498,731 | $4.67 | $4.78 | $4.67 |
21 Jul 2023 | $4.67 | $-0.06 | -1.27% | 90,699 | $4.75 | $4.76 | $4.65 |
20 Jul 2023 | $4.73 | $-0.04 | -0.84% | 163,804 | $4.81 | $4.81 | $4.67 |
19 Jul 2023 | $4.77 | $0.06 | 1.27% | 405,856 | $4.89 | $4.90 | $4.75 |
18 Jul 2023 | $4.71 | $0.12 | 2.61% | 259,950 | $4.53 | $4.76 | $4.53 |
17 Jul 2023 | $4.59 | $0.07 | 1.55% | 96,920 | $4.55 | $4.60 | $4.49 |
14 Jul 2023 | $4.52 | $-0.03 | -0.66% | 83,659 | $4.50 | $4.60 | $4.50 |
13 Jul 2023 | $4.55 | $0.08 | 1.79% | 161,971 | $4.50 | $4.58 | $4.48 |
12 Jul 2023 | $4.47 | $0.06 | 1.36% | 318,213 | $4.42 | $4.54 | $4.42 |
11 Jul 2023 | $4.41 | $0.06 | 1.38% | 40,980 | $4.38 | $4.44 | $4.35 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
17 Apr 2023 | Ann Custin | Buy | 9 | $36,844 |
On-market trade.
|
13 Apr 2023 | Patrick Blake | Buy | 3 | $12,591 |
On-market trade.
|
12 Apr 2023 | Patrick Blake | Buy | 6 | $24,749 |
On-market trade.
|
30 Mar 2023 | Carolyn Myers | Buy | 20 | $74,527 |
On-market trade.
|
29 Mar 2023 | Kathryn MacFarlane | Buy | 20 | $76,156 |
On-market trade.
|
27 Mar 2023 | Frank Condella | Buy | 3 | $11,291 |
On-market trade.
|
24 Mar 2023 | Frank Condella | Buy | 17 | $62,691 |
On-market trade.
|
16 Mar 2023 | Shawn O'Brien | Issued | 364 | $1,299,847 |
Issue of securities. 364,103 Performance Rights
|
30 Sep 2022 | Scott Richards | Transfer | 5 | $1,535,976 |
Off-market transfer. Assuming off-market transfer
|
30 Sep 2022 | Scott Richards | Transfer | 5 | $1,535,976 |
Off-market transfer. Assuming off-market transfer
As per announcement on 04-10-2022 |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Frank Condella | Non-Executive DirectorNon-Executive Chairman | May 2018 |
Mr Condella has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as CEO of Skyepharma Plc, President of European operations at IVAX (Teva), CEO of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella's previous board experience includes Chairman of Skyepharma Plc until it merged with Vectura, Vice Chairman of Vectura Plc, Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, and Chairman of the PKD Foundation. He currently also serves as an Independent Director for Fertin Pharma A/S (Denmark) and Palladio Biosciences Inc (US). Mr Condella is a member of Mayne Pharma's Science, Technology and Medical Committee.
|
Professor Bruce Gregory Robinson | Non-Executive Director | Aug 2014 |
Professor Robinson is former Dean of University of Sydney's Sydney Medical School. He has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, he has been Chairman of Hoc Mai Foundation, a program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Prof Robinson is Chairman of the Science, Technology and Medical Committee.
|
Mr Patrick J Blake | Non-Executive Director | Jun 2018 |
Mr Blake has over 30 years of healthcare industry experience including more than 20 years at McKesson Corporation one of the healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focussed on the US specialty/biotech sector which was McKesson's business for three years during his leadership. He was also President of Customer Operations for McKesson Pharmaceutical (US) from 2000 to 2006, led sales and operations for the wholesale distribution of branded and generic pharmaceuticals and other related products. Mr Blake is a Member of the Risk and People Committee.
|
Ms Ann Custin | Non-Executive Director | Mar 2022 |
Ms Custin has almost 40 years of experience in the healthcare sector. She is an experienced executive with healthcare commercial experience across the US, Europe and Asia. She also has experience in strategy, financial planning and reporting, portfolio management, sales operations, manufacturing, risk management, business and corporate development. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions (now Siemens Healthineers), a medical technology company. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is currently a director of two women's health focused companies - ASX-listed Volpara Health and NASDAQ-listed Establishment Labs. She will also join Mayne Pharma's Risk Committee effective 23/03/2022.
|
Dr Kathryn MacFarlane | Non-Executive Director | Feb 2022 |
Dr MacFarlane has more than 30 years of experience in the pharmaceutical industry. She also has experience in launch planning, sales and marketing, product reimbursement, strategy, business development and clinical R&D. Her experience spans multiple therapeutic areas including women's health and dermatology. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women's Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at ParkeDavis (now Pfizer). Dr MacFarlane is a Director of RespireRx Pharmaceuticals, Inc., a member of the Purdue University School of Pharmacy Dean's Advisory Council and a Founding Member and Advisor to IPhO. She also serves on the Board of Directors for INMED Partnerships for Children, an NGO.
|
Mr David Petrie | Non-Executive Director | Sep 2022 |
Mr Petrie is an M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare. He is also a member of Risk Committee.
|
Mr Shawn Patrick O'Brien | Chief Executive OfficerManaging Director | Oct 2022 |
Mr O'Brien is the founding partner of Key BioPharma Partners. Previously he was the Chairman and CEO of Genomind for three years, President and CEO of Cipher Pharmaceuticals (TSX: CPH) for over two years. He was also Founder, President and CEO of AltheRx Pharmaceuticals, a private biopharma development company. Other roles held include President and CEO of Profectus BioSciences Inc. a private biotech company focused on the treatment of chronic infections and President and CEO of Solstice Neurosciences, a biotech company focused on the movement disorders market. Mr O'Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area. Mr O'Brien began his career at the Upjohn Company of Canada (part of Pfizer). Mr O'Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress. He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC.
|
Ms Laura Loftus | Company Secretary | Mar 2020 |
-
|
Peter Paltoglou | Chief Financial Officer |
-
|
|
Laura Loftus | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
No top 20 shareholder's information disclosed | 0 | 0.00% |